Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

About this update from Agios Pharmaceuticals, Inc.

[{"type":"image","alt":"Agios Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Agios Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/f130e1d6d26430b354ab1508b7720e57"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/It4G_eD3NorQnYU4NVTyHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2/https://media.zenfs.com/en/globenewswire.com/f130e1d6d26430b354ab1508b7720e57","width":300,"height":54},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/It4G_eD3NorQnYU4NVTyHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2/https://media.zenfs.com/en/globenewswire.com/f130e1d6d26430b354ab1508b7720e57","width":300,"height":54}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session","length":132,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":132,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Company to host investor conference call and webcast during EHA 2026 on Saturday, June 13, at 9:00 a.m. ET (3:00 p.m. CEST)","length":123,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":123,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on mitapivat, an oral pyruvate kinase (PK) activator, will be featured in oral and poster presentations during the 31st European Hematology Association (EHA) Congress (EHA 2026) in Stockholm, Sweden, June 11-14, 2026.","length":463,"tagName":"p"},{"type":"text","content":"“Our presentations at EHA 2026 build on over a decade of clinical and preclinical research that has consistently demonstrated the transformative potential of mitapivat as a disease-modifying oral medicine for hemolytic anemias, including sickle cell disease and thalassemia,” said Sarah Gheuens, M.D., Ph.D., Chief Medical Officer and Head of R&D, Agios. “The plenary session for our RISE UP Phase 3 trial is an important opportunity to present new data showcasing the strong anti-hemolytic profile of mitapivat and its potential ...

More updates from Agios Pharmaceuticals, Inc.